First proof of bismuth oxide nanoparticles as efficient radiosensitisers on highly radioresistant cancer cells.
This study provides the first proof of the novel application of bismuth oxide as a radiosensitiser. It was shown that on the highly radioresistant 9L gliosarcoma cell line, bismuth oxide nanoparticles sensitise to both kilovoltage (kVp) or megavoltage (MV) X-rays radiation. 9L cells were exposed to a concentration of 50μg.mL-1of nanoparticle before irradiation at 125kVp and 10MV. Sensitisation enhancement ratios of 1.48 and 1.25 for 125kVp and 10MV were obtained in vitro, respectively. The radiation enhancement of the nanoparticles is postulated to be a combination of the high Z nature of the bismuth (Z=83), and the surface chemistry. Monte Carlo simulations were performed to elucidate the physical interactions between the incident radiation and the nanoparticle. The results of this work show that Bi2O3nanoparticles increase the radiosensitivity of 9L gliosarcoma tumour cells for both kVp and MV energies. Monte Carlo simulations demonstrate the advantage of a platelet morphology.
School of Chemistry, University of Wollongong, Northfields Ave, NSW 2522, Australia; Institute of Superconducting and Electronic Materials (ISEM), University of Wollongong, Squires Way, North Wollongong, NSW 2500, Australia; Illawarra Health and Medical Research Institute (IHMRI), University of Wollongong, Northfields Ave, NSW 2522, Australia.
Callum
C
Stewart
Institute of Superconducting and Electronic Materials (ISEM), University of Wollongong, Squires Way, North Wollongong, NSW 2500, Australia; Illawarra Health and Medical Research Institute (IHMRI), University of Wollongong, Northfields Ave, NSW 2522, Australia.
Konstantin
K
Konstantinov
Centre of Medical and Radiation Physics (CMRP), University of Wollongong, Northfields Avenue, Wollongong, NSW 2522, Australia.
Sally
S
McKinnon
Illawarra Health and Medical Research Institute (IHMRI), University of Wollongong, Northfields Ave, NSW 2522, Australia; Centre of Medical and Radiation Physics (CMRP), University of Wollongong, Northfields Avenue, Wollongong, NSW 2522, Australia.
Susanna
S
Guatelli
Illawarra Health and Medical Research Institute (IHMRI), University of Wollongong, Northfields Ave, NSW 2522, Australia; Centre of Medical and Radiation Physics (CMRP), University of Wollongong, Northfields Avenue, Wollongong, NSW 2522, Australia.
Michael
M
Lerch
Illawarra Health and Medical Research Institute (IHMRI), University of Wollongong, Northfields Ave, NSW 2522, Australia; Centre of Medical and Radiation Physics (CMRP), University of Wollongong, Northfields Avenue, Wollongong, NSW 2522, Australia.
Anatoly
A
Rosenfeld
Illawarra Health and Medical Research Institute (IHMRI), University of Wollongong, Northfields Ave, NSW 2522, Australia; Centre of Medical and Radiation Physics (CMRP), University of Wollongong, Northfields Avenue, Wollongong, NSW 2522, Australia. Electronic address: moeava@uow.edu.au.
Moeava
M
Tehei
Illawarra Health and Medical Research Institute (IHMRI), University of Wollongong, Northfields Ave, NSW 2522, Australia; Centre of Medical and Radiation Physics (CMRP), University of Wollongong, Northfields Avenue, Wollongong, NSW 2522, Australia; Radiation Oncology Department, Prince of Wales Hospital, Randwick, High Street, NSW 2031, Australia.
Stéphanie
S
Corde
D001729:Bismuth / Q000737:chemistry* / Q000494:pharmacology* / Q000633:toxicity; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D018316:Gliosarcoma / Q000473:pathology; D006801:Humans; D009010:Monte Carlo Method; D053758:Nanoparticles; D011836:Radiation Tolerance / Q000187:drug effects*; D011838:Radiation-Sensitizing Agents / Q000737:chemistry* / Q000494:pharmacology* / Q000633:toxicity
D011838:Radiation-Sensitizing Agents; C033301:bismuth oxide; D001729:Bismuth
Bismuth oxide nanoparticles; Dose enhancement; Monte Carlo simulation; Radiosensitisers